

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

	Child				Adult			
	Prior Assessment Period		Current Assessment Period		Prior Assessment Period		Current Assessment Period	
Vaccine Cost Estimates								
Estimated Non-Flu Vaccine Cost Based on Current CDC Prices		\$ 19,261,848		\$ 17,732,728		\$ 10,607,107		\$ 11,429,417
Estimated Flu Vaccine Cost Based on Current CDC Prices		\$ 954,371		\$ 924,831		\$ 9,138,870		\$ 8,957,604
Estimated COVID-19 Vaccine Cost Based on Current CDC Prices		\$ 2,818,640		\$ 2,205,245		\$ 13,387,110		\$ 13,220,600
Total Estimated Vaccine Cost Based on Current CDC Prices		\$ 23,034,859		\$ 20,862,804		\$ 33,133,086		\$ 33,607,621
Provision for Vaccine Cost Increase	0.0%	\$ -	1.1%	\$ 225,427	1.6%	\$ 530,355	4.1%	\$ 1,380,187
Total Estimated Vaccine Costs		\$ 23,034,859		\$ 21,088,231		\$ 33,663,442		\$ 34,987,807
Total Administrative and Operating Costs		\$ 4,713,366		\$ 4,504,896		\$ 5,545,857		\$ 5,236,911
Total Reserves / Working Capital		\$ (1,983,984)		\$ (1,854,101)		\$ 1,783,186		\$ (6,310,595)
Total Assessable Covered Lives Estimate		86,479		85,424		547,601		560,883
Assessment Calculation								
Total Assessment		\$ 25,764,241		\$ 23,739,026		\$ 40,992,485		\$ 33,914,123
Total Assessment Per Covered Life		\$ 297.92		\$ 277.90		\$ 74.86		\$ 60.47
Monthly Assessment Per Covered Life Calculated / % Change		\$ 24.83	-6.7%	\$ 23.16		\$ 6.24	-19.2%	\$ 5.04
Preliminary Projection								
Run Rate Monthly Assessment Per Covered Life		\$ 26.74		\$ 24.97		\$ 5.97		\$ 5.98
Preliminary Assessment projection	0.0%	\$ 26.74	1.1%	\$ 25.24	1.6%	\$ 6.06	4.1%	\$ 6.22
Preliminary Assessment increase		7.70%		8.98%		-2.82%		23.48%
Program Metrics								
Administrative and Operational Costs as % of Vaccine Costs		20.46%		21.36%		16.47%		14.97%
CDC Vaccine Costs as % Below Private Purchase Costs		-21.88%		-27.30%		-18.58%		-29.79%

Notes:

Proposed rates for Current Assessment Period of \$23.16 (child) and \$5.04 (adult) reflect 100% release of excess funds.

Assessment Rate variations based on decreased use of excess funds (75%, 50%, 25%, 0%) reflected on page x.

Final decision to be discussed during May 14, 2024 RIVAP VAC Sub-Committee Assessment Meeting.

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Change in Assessment from Prior Year

	Child			Adult		
	Cost	PMPM	% Change	Cost	PMPM	% Change
2024 Fiscal Year Ending June 30, 2024	\$25,764,241	\$ 24.83		\$40,992,485	\$ 6.24	
Change In:						
Contribution Enrollees		\$ 0.30	1.2%		\$ (0.15)	-2.4%
Estimated Vaccine Cost	\$ (2,172,055)	\$ (2.12)	-8.5%	\$ 474,535	\$ 0.07	1.1%
Provision For Vaccine Cost Increase	\$ 225,427	\$ 0.22	0.9%	\$ 849,831	\$ 0.13	2.1%
Administrative Costs	\$ (51,496)	\$ (0.05)	-0.2%	\$ (445,187)	\$ (0.07)	-1.1%
Operational Costs	\$ (156,975)	\$ (0.15)	-0.6%	\$ 136,240	\$ 0.02	0.3%
Reserve/Working Capital	\$ 129,884	\$ 0.13	0.5%	\$ (8,093,781)	\$ (1.20)	-19.2%
2025 Fiscal Year Ending June 30, 2025	\$23,739,026	\$ 23.16	-6.7%	\$33,914,123	\$ 5.04	-19.2%

Comments

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Scenario Comparison

	Assessment Rate Scenario #1 (100% release)						Assessment Rate Scenario #2 (75% release)					
	Child			Adult			Child			Adult		
	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment
Contribution Enrollees			85,424			560,883			85,424			560,883
Estimated Vaccine Cost	\$ 20,862,804	\$ 20.35		\$ 33,607,621	\$ 4.99		\$ 20,862,804	\$ 20.35		\$ 33,607,621	\$ 4.99	
Provision For Vaccine Cost Increase	\$ 225,427	\$ 0.22		\$ 1,380,187	\$ 0.21		\$ 225,427	\$ 0.22		\$ 1,380,187	\$ 0.21	
Administrative Costs	\$ 2,524,928	\$ 2.46		\$ 3,654,062	\$ 0.54		\$ 2,558,838	\$ 2.50		\$ 3,808,382	\$ 0.57	
Operational Costs	\$ 1,979,967	\$ 1.93		\$ 1,582,849	\$ 0.24		\$ 1,979,967	\$ 1.93		\$ 1,582,849	\$ 0.24	
Reserve/Working Capital	\$ (1,854,101)	\$ (1.81)		\$ (6,310,595)	\$ (0.94)		\$ (1,515,007)	\$ (1.48)		\$ (4,767,396)	\$ (0.71)	
Total Assessment	\$ 23,739,026	\$ 23.16		\$ 33,914,123	\$ 5.04		\$ 24,112,029	\$ 23.52		\$ 35,611,642	\$ 5.29	

	Assessment Rate Scenario #3 (50% release)						Assessment Rate Scenario #4 (25% release)						Assessment Rate Scenario #5 (0% release)					
	Child			Adult			Child			Adult			Child			Adult		
	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment	Cost	PMPM	Enrollment
Contribution Enrollees			85,424			560,883			85,424			560,883			85,424			560,883
Estimated Vaccine Cost	\$ 20,862,804	\$ 20.35		\$ 33,607,621	\$ 4.99		\$ 20,862,804	\$ 20.35		\$ 33,607,621	\$ 4.99		\$ 20,862,804	\$ 20.35		\$ 33,607,621	\$ 4.99	
Provision For Vaccine Cost Increase	\$ 225,427	\$ 0.22		\$ 1,380,187	\$ 0.21		\$ 225,427	\$ 0.22		\$ 1,380,187	\$ 0.21		\$ 225,427	\$ 0.22		\$ 1,380,187	\$ 0.21	
Administrative Costs	\$ 2,592,747	\$ 2.53		\$ 3,962,702	\$ 0.59		\$ 2,626,656	\$ 2.56		\$ 4,117,021	\$ 0.61		\$ 2,660,566	\$ 2.60		\$ 4,271,341	\$ 0.63	
Operational Costs	\$ 1,979,967	\$ 1.93		\$ 1,582,849	\$ 0.24		\$ 1,979,967	\$ 1.93		\$ 1,582,849	\$ 0.24		\$ 1,979,967	\$ 1.93		\$ 1,582,849	\$ 0.24	
Reserve/Working Capital	\$ (1,175,914)	\$ (1.15)		\$ (3,224,198)	\$ (0.48)		\$ (836,821)	\$ (0.82)		\$ (1,680,999)	\$ (0.25)		\$ (497,727)	\$ (0.49)		\$ (137,801)	\$ (0.02)	
Total Assessment	\$ 24,485,031	\$ 23.89		\$ 37,309,160	\$ 5.54		\$ 24,858,034	\$ 24.25		\$ 39,006,679	\$ 5.80		\$ 25,231,037	\$ 24.61		\$ 40,704,197	\$ 6.05	

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Comparison to Prior Period

		Cost Per Dose	Doses	Cost
Total Pediatric	Prior Period Projected	\$ 88.39	260,595	\$ 23,034,859
	Current Period Projected	\$ 85.45	246,795	\$ 21,088,231
	Variance	\$ (2.95)	-13,800	\$ (1,946,628)
	% Variance	-3.3%	-5.3%	-8.5%
Total Adult	Prior Period Projected	\$ 64.43	522,461	\$ 33,663,442
	Current Period Projected	\$ 63.74	548,910	\$ 34,987,807
	Variance	\$ (0.69)	26,449	\$ 1,324,366
	% Variance	-1.1%	5.1%	3.9%
Pediatric	Prior Period Projected	\$ 110.04	175,051	\$ 19,261,848
	Current Period Projected	\$ 112.60	158,655	\$ 17,864,253
	Variance	\$ 2.56	-16,396	\$ (1,397,595)
	% Variance	2.3%	-9.4%	-7.3%
Adult	Prior Period Projected	\$ 83.68	133,100	\$ 11,137,462
	Current Period Projected	\$ 88.37	135,800	\$ 12,000,888
	Variance	\$ 4.69	2,700	\$ 863,426
	% Variance	5.6%	2.0%	7.8%
Pediatric Flu	Prior Period Projected	\$ 15.93	59,920	\$ 954,371
	Current Period Projected	\$ 16.28	58,510	\$ 952,576
	Variance	\$ 0.35	-1,410	\$ (1,796)
	% Variance	2.2%	-2.4%	-0.2%
Adult Flu	Prior Period Projected	\$ 34.14	267,660	\$ 9,138,870
	Current Period Projected	\$ 35.97	253,110	\$ 9,105,289
	Variance	\$ 1.83	-14,550	\$ (33,581)
	% Variance	5.4%	-5.4%	-0.4%
Pediatric COVID-19	Prior Period Projected	\$ 110.00	25,624	\$ 2,818,640
	Current Period Projected	\$ 76.66	29,630	\$ 2,271,402
	Variance	\$ (33.34)	4,006	\$ (547,238)
	% Variance	-30.3%	15.6%	-19.4%
Adult COVID-19	Prior Period Projected	\$ 110.00	121,701	\$ 13,387,110
	Current Period Projected	\$ 86.76	160,000	\$ 13,881,630
	Variance	\$ (23.24)	38,299	\$ 494,520
	% Variance	-21.1%	31.5%	3.7%

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Summary Statistics

	Current Assessment Period										
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	246,795	\$ 20,862,804	\$ 28,697,393	\$ 29,005,491	\$ -	1.1%	\$ 225,427	0.0%	\$ -	\$ -	\$ 21,088,231
Total Adult	548,910	\$ 33,607,621	\$ 47,868,068	\$ 49,916,386	\$ -	4.1%	\$ 1,380,187	0.0%	\$ -	\$ -	\$ 34,987,807
Pediatric	158,655	\$ 17,732,728	\$ 24,479,722	\$ 24,661,290	\$ -	0.7%	\$ 131,525	0.0%	\$ -	\$ -	\$ 17,864,253
Adult	135,800	\$ 11,429,417	\$ 17,955,959	\$ 18,853,757	\$ -	5.0%	\$ 571,471	0.0%	\$ -	\$ -	\$ 12,000,888
Pediatric Flu	58,510	\$ 924,831	\$ 1,238,271	\$ 1,275,419	\$ -	3.0%	\$ 27,745	0.0%	\$ -	\$ -	\$ 952,576
Adult Flu	253,110	\$ 8,957,604	\$ 10,297,108	\$ 10,466,879	\$ -	1.6%	\$ 147,686	0.0%	\$ -	\$ -	\$ 9,105,289
Pediatric COVID-19	29,630	\$ 2,205,245	\$ 2,979,400	\$ 3,068,782	\$ -	3.0%	\$ 66,157	0.0%	\$ -	\$ -	\$ 2,271,402
Adult COVID-19	160,000	\$ 13,220,600	\$ 19,615,000	\$ 20,595,750	\$ -	5.0%	\$ 661,030	0.0%	\$ -	\$ -	\$ 13,881,630

	Prior Assessment Period										
	Dose Quantity	Vaccine Cost	Private Cost	Projected Private Cost	Stock Separation/ Other Cost	Cost Increase Assumption	Provision for Cost/ Dose Increase	Utilization Increase Assumption	Provision for Utilization Increase	Vaccine Waste Allowance	Projected Vaccine Cost
Total Pediatric	260,595	\$ 23,034,859	\$ 30,471,592	\$ 27,652,952	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 23,034,859
Total Adult	522,461	\$ 33,133,086	\$ 40,694,268	\$ 41,543,750	\$ -	1.6%	\$ 530,355	0.0%	\$ -	\$ -	\$ 33,663,442
Pediatric	175,051	\$ 19,261,848	\$ 26,407,841	\$ 26,407,841	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 19,261,848
Adult	133,100	\$ 10,607,107	\$ 16,989,642	\$ 17,839,124	\$ -	5.0%	\$ 530,355	0.0%	\$ -	\$ -	\$ 11,137,462
Pediatric Flu	59,920	\$ 954,371	\$ 1,245,111	\$ 1,245,111	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 954,371
Adult Flu	267,660	\$ 9,138,870	\$ 10,317,516	\$ 10,317,516	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 9,138,870
Pediatric COVID-19	25,624	\$ 2,818,640	\$ 2,818,640	\$ -	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 2,818,640
Adult COVID-19	121,701	\$ 13,387,110	\$ 13,387,110	\$ 13,387,110	\$ -	0.0%	\$ -	0.0%	\$ -	\$ -	\$ 13,387,110

	CDC Cost to Private Cost %	Difference Between CDC Cost/ Dose and Private Cost/ Dose	Cost Change Due to Price Change	% Change in Cost/ Dose	Change in Dose Quantity	Cost at Prior Year Dose Quantity	Cost Change Due to Dose Change	% Cost Change Due to Dose Change	Total Cost Change
Total Pediatric	-27.3%	\$ (1,947.28)	\$ 483,255	2.1%	(13,800)	\$ 23,518,114	\$ (2,655,311)	-11.3%	\$ (2,172,055)
Total Adult	-29.8%	\$ (1,827.57)	\$ (2,719,932)	-8.2%	26,449	\$ 30,413,154	\$ 3,194,467	10.5%	\$ 474,535
Pediatric	-27.6%	\$ (1,697.36)	\$ 1,390,333	7.2%	(16,396)	\$ 20,652,181	\$ (2,919,453)	-14.1%	\$ (1,529,120)
Adult	-36.3%	\$ (1,468.83)	\$ 307,189	2.9%	2,700	\$ 10,914,296	\$ 515,122	4.7%	\$ 822,311
Pediatric Flu	-25.3%	\$ (56.31)	\$ 4,468	0.5%	(1,410)	\$ 958,840	\$ (34,009)	-3.5%	\$ (29,541)
Adult Flu	-13.0%	\$ (62.16)	\$ 303,987	3.3%	(14,550)	\$ 9,442,857	\$ (485,253)	-5.1%	\$ (181,266)
Pediatric COVID-19	-26.0%	\$ (193.60)	\$ (911,546)	-32.3%	4,006	\$ 1,907,094	\$ 298,151	15.6%	\$ (613,395)
Adult COVID-19	-32.6%	\$ (296.58)	\$ (3,331,108)	-24.9%	38,299	\$ 10,056,002	\$ 3,164,598	31.5%	\$ (166,510)

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Top Vaccines - Child-

Vaccine	Brandname/ Tradename	NDC	CDC Cost/ Dose	Dose Quantity	Vaccine Cost	% of Total	Private Sector Cost/ Dose	Private Cost	\$ Savings per Dose
HPV – Human Papillomavirus 9-valent	Gardasil®9	00006-4121-02	\$ 240.30	20,000	\$ 4,806,040	23%	\$ 287.54	\$ 5,750,700	\$ 47.23
Pneumococcal	Prevnar 20TM	00005-2000-10	\$ 185.09	10,750	\$ 1,989,718	10%	\$ 261.56	\$ 2,811,770	\$ 76.47
DTaP-IPV-HIB-HEPB	Vaxelis™	63361-0243-15	\$ 100.59	15,800	\$ 1,589,306	8%	\$ 150.85	\$ 2,383,430	\$ 50.26
Meningococcal Conjugate (Groups A, C, W and Y)	MenQuadfi™	49281-0590-05	\$ 111.05	13,500	\$ 1,499,175	7%	\$ 166.98	\$ 2,254,284	\$ 55.93
MENB – Meningococcal Group B	Bexsero®	58160-0976-20	\$ 150.03	8,800	\$ 1,320,229	6%	\$ 223.75	\$ 1,968,965	\$ 73.72
Rotavirus, Live, Oral, Oral	Rotarix®	58160-0740-21	\$ 108.49	10,900	\$ 1,182,541	6%	\$ 138.74	\$ 1,512,277	\$ 30.25
MMR/Varicella	ProQuad®	00006-4171-00	\$ 178.35	6,550	\$ 1,168,173	6%	\$ 270.15	\$ 1,769,469	\$ 91.80
Varicella	Varivax®	00006-4827-00	\$ 144.27	6,880	\$ 992,578	5%	\$ 174.32	\$ 1,199,342	\$ 30.05
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0575-15	\$ 395.00	2,225	\$ 878,875	4%	\$ 519.75	\$ 1,156,444	\$ 124.75
Respiratory Syncytial Virus (RSV)	BeyfortusTM	49281-0574-15	\$ 395.00	1,700	\$ 671,500	3%	\$ 519.75	\$ 883,575	\$ 124.75

Rhode Island Fiscal Year Ending June 30, 2025 Assessment

Top Vaccines - Adult-

Vaccine	Brandname/ Tradename	NDC	CDC Cost/ Dose	Dose Quantity	Vaccine Cost	% of Total	Private Sector Cost/		\$ Savings per Dose
							Dose	Private Cost	
Covid-19 (Age 12 years and older)	Spikevax™	80777-0102-95	\$ 81.61	90,000	\$ 7,344,900	22%	\$ 128.00	\$ 11,520,000	\$ 46.39
Pneumococcal	Prevnar 20™	00005-2000-10	\$ 176.84	35,000	\$ 6,189,260	18%	\$ 261.56	\$ 9,154,600	\$ 84.72
Covid-19 (Age 12 years and older)	Comirnaty®	00069-2377-10	\$ 85.10	67,000	\$ 5,701,700	17%	\$ 115.00	\$ 7,705,000	\$ 29.90
Influenza	Fluzone HD	0	\$ 64.73	50,000	\$ 3,236,450	10%	\$ 64.73	\$ 3,236,450	\$ -
Influenza	Fluad (65+ yrs)	0	\$ 64.21	50,000	\$ 3,210,600	10%	\$ 64.21	\$ 3,210,600	\$ -
Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis	Adacel®	49281-0400-20	\$ 28.49	58,000	\$ 1,652,420	5%	\$ 47.83	\$ 2,774,256	\$ 19.34
Influenza	Fluzone®	49281-0424-50	\$ 14.34	95,000	\$ 1,362,300	4%	\$ 20.68	\$ 1,964,505	\$ 6.34
Influenza	Flucelvax® TIV	70461-0654-03	\$ 19.76	58,110	\$ 1,148,254	3%	\$ 32.45	\$ 1,885,553	\$ 12.69
HPV-Human Papillomavirus 9 Valent	Gardasil®9	00006-4121-02	\$ 178.33	4,800	\$ 855,979	3%	\$ 287.54	\$ 1,380,168	\$ 109.21
Hepatitis B Adult	Heplisav-B™	43528-0003-05	\$ 74.94	8,700	\$ 651,978	2%	\$ 140.60	\$ 1,223,220	\$ 65.66